Design of a potent novel endotoxin antagonist

Surgery

Volumn 122, Issue 2, 1997, Pages 380-385

  Uknis, Marc E ^a   Wasiluk, Karen R ^a   Acton, Robert D ^a   Klaerner, Hans G ^a   Dahlberg, Peter S ^a   Ilyina, Elena E ^a   Haseman, Judith R ^a   Gray, Beulah H ^a   Mayo, Kevin H ^a   Dunn, David L ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERICIDAL PERMEABILITY INCREASING PROTEIN; ENDOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

AMINO ACID SEQUENCE; CONFERENCE PAPER; ENDOTOXEMIA; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; PROTEIN SYNTHESIS; SEPSIS; SEQUENCE ANALYSIS; STRUCTURE ACTIVITY RELATION;

EID: 12644278299     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(97)90030-1     Document Type: Conference Paper

References (14)

1. Burd RS, Cody CS, Dunn DL. Immunotherapy of gram-negative bacterial sepsis: medical intelligence unit. Austin (TX): RG Landes Company; 1992.
2. Tracey KJ, Lowry SF. The role of cytokine mediators in septic shock. Adv Surg 1990;23:21-56.
3. Weiss J, Elsbach P, Olsson I, Odeberg H. Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. J Biol Chem 1978;253:2664-72.
4. Hovde CJ, Gray BH. Physiologic effects of a bactericidal protein from human polymorphonuclear leukocytes on Pseudomonas aeruginosa. Infect Immun 1986;52:90-5.
5. Hoess A, Watson S, Siber GR, Liddington R. Crystal structure of an endotoxin-neutralizing protein from the horseshoe crab: Limulus anti-LPS factor, at 1.5 angstroms resolution. EMBO J 1993;12:3351-6.
6. Battafarano RJ, Dahlberg PS, Ratz CA, Johnston JW, Gray BH, Haseman JR, et al. Peptide derivatives of three distinct lipopolysaccharide binding proteins inhibit lipopolysaccharide-induced tumor necrosis factor-alpha secretion in vitro. Surgery 1995;118:318-24.
7. Dahlberg PS, Acton RD, Battafarano RJ, Uknis ME, Ratz CA, Johnston JW, et al. A novel endotoxin antagonist attenuates tumor necrosis factor-alpha secretion. J Surg Res 1996;63:44-8.
8. Ilyina E, Milius R, Mayo KH. Synthetic peptides probe folding initiation sites in platelet factor-4: stable side chain reversal found within the hydrophobic sequence LIATLKNGRKISL. Biochemistry 1994;33:13436-44.
9. Ilyina E, Mayo KH. Multiple native-like conformations trapped via self-association-induced hydrophobic collapse of the 33-residue β-sheet domain from platelet factor 4. Biochem J 1995;306:407-19.
10. Mayo KH, Ilyina E, Park H. A recipe for designing water-soluble, β-sheet forming peptides. Protein Sci 1996;5:1301-15.
11. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. Treatment of gram negative bacteremia in septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1991;324:429-36.
12. The CHESS trial study group: treatment of septic shock with human monoclonal antibody HA-1A: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1994;121:1-5.
13. Greenman RL, Schein RMH, Martin MA, et al. A controlled trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991;266:1097-102.
14. Bone RC, Balk RA, Fein AM, Perl TM, Wenzel RP, Reines D, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 1995;23:994-1005.